In this episode of the BackTable Urology Podcast, Dr. Ashish Kamat discusses contemporary management of high-risk, non-muscle-invasive bladder cancer (NMIBC) and his thoughts into the future of this arena.

---

CHECK OUT OUR SPONSOR

Siemens Healthineers Theranostics

https://www.siemens-healthineers.com/en-us/clinical-specialities/theranostics

---

SYNPOSIS

Dr. Kamat explores the evolving role of BCG and potential alternative therapies such as gemcitabine and docetaxel. He also covers effective clinical management, emerging clinical trials, and nuanced decision-making principles for radical cystectomy. Finally, the conversation touches on Dr. Kamat’s expert insights regarding the future of NMIBC management, including predictive biomarkers and personalized medicine.

---

TIMESTAMPS

00:00 - Introduction

03:56 - Initial Diagnosis and Workup

12:22 - High-Grade Bladder Cancer

22:37 - BCG and Alternative Treatments

31:30 - BCG Unresponsive Disease

36:56 - Novel Intravesical and Systemic Therapies

46:45 - Future Directions

---

RESOURCES

Related BackTable episodes:

https://www.backtable.com/shows/urology/podcasts/64/management-of-bcg-refractory-nmibc

https://www.backtable.com/shows/urology/podcasts/157/the-bladder-cancer-matters-podcast

https://www.backtable.com/shows/urology/podcasts/103/adjuvant-therapy-for-high-risk-bladder-cancer